Instrument Inactif

Autres langues Cortex Pharmaceuticals OTC Bulletin Board

Actions

US2205243007

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

19/11	RespireRx Pharmaceuticals annonce l'obtention d'une subvention du NIH/NINDS et la signature d'un accord de licence de brevet modifié	CI
20/03/24	RespireRx Pharmaceuticals Inc. annonce la publication de résultats de recherche préclinique démontrant la capacité du CX1739, sa principale AMPAkine clinique, à améliorer la fonction vésicale après une lésion de la moelle épinière.	CI

Autres langues

19/11	RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement
18/11	RespireRx Pharmaceuticals Inc. announced that it expects to receive $45 million in funding
10/02/25	RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
08/07/24	RespireRx Pharmaceuticals : Material Agreement Form 8 K
04/07/24	Stocks Under 1¢: June 2024 Gains, July 2024 Watchlist SMCE, SPZI, RSPI, HALB, BIEI, RJDG
29/05/24	RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
10/04/24	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding
20/03/24	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
20/03/24	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
13/02/24	RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
13/02/24	RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine
22/01/24	RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
22/01/24	RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors
04/01/24	Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
04/01/24	RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
11/12/23	RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
17/11/23	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
13/10/23	Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)
12/10/23	RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
02/10/23	RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K
26/09/23	Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
21/08/23	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
10/08/23	CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN
09/08/23	RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
13/06/23	RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K